
|Articles|April 15, 2004
FDA expedites review of kidney cancer drug
The FDA has added BAY 43-9006, an investigational treatment for metastatic renal cell carcinoma, to its fast track program.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
NDV-01 produces robust 9-month results in high-risk NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
5

















